Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790370 · ClinicalTrials.gov registry record · Phase 4
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
A Phase 4 study of Pulmonary Embolism, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- Phase 4
- Development phase
- 544
- Enrollment target
- 20
- Study locations
NCT04790370: Active Phase 4 study of Pulmonary Embolism, sponsored by Boston Scientific Corporation.
NCT04790370 is a Phase 4 study of Pulmonary Embolism that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 544 participants, below the 3,047-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04790370, a Phase 4 study of Pulmonary Embolism, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 544 participants
- Enrollment target
- 20
- Study locations
Study Summary
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is better than the other at reducing the risk of death and other serious problems.
Primary Outcome
death resulting from PE
Conditions Studied
Interventions
- DRUG Anticoagulation with heparin
- DEVICE EkoSonicTM Endovascular System
Study Locations (20)
Georgia
- Piedmont Hospital - Atlanta
- Emory University Hospital - Atlanta
- Augusta University - Augusta
New York
- Mount Sinai Medical Center - New York
- Columbia University Medical Center - New York
- Lenox Hill Hospital - New York
Michigan
- University of Michigan Hospitals - Ann Arbor
- Henry Ford Hospital - Detroit
New Jersey
- Cooper Hospital - University Medical Center - Camden
- Newark Beth Israel Medical Center - Newark
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Cedars - Sinai Medical Center - Los Angeles
Delaware
- Christiana Hospital - Newark
Indiana
- Methodist Hospitals - Merrillville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What the registry record for NCT04790370 still lists
NCT04790370 is an interventional study that assigns participants to a tested intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, below the 3,047-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Anticoagulation with heparin is the first listed.
NCT04790370 names 20 study sites across 14 states, led by Georgia, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT04790370 about?
NCT04790370 is a clinical study titled "Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism". There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thin...
What is the current status of trial NCT04790370?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 544 participants. The study started on 2021-08-02. Estimated completion is 2026-08.
What conditions does trial NCT04790370 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT04790370?
The interventions under investigation include: Anticoagulation with heparin (DRUG), EkoSonicTM Endovascular System (DEVICE).
Who is sponsoring clinical trial NCT04790370?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04790370 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04790370's enrollment target sits among peer trials
544 12th of 48 higher than 37 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
COMPLETED · Phase 4
-
Detection of Pulmonary Embolism With CECT
COMPLETED · Phase 4
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI